Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. (2022)

First Author: ACTIV-3/Therapeutics For Inpatients With COVID-19 (TICO) Study Group
Attributed to:  Respiratory infections funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1473-3099(21)00751-9

PubMed Identifier: 34953520

Publication URI: http://europepmc.org/abstract/MED/34953520

Type: Journal Article/Review

Volume: 22

Parent Publication: The Lancet. Infectious diseases

Issue: 5

ISSN: 1473-3099